Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23916902 | 0.85 | JAK1 (0.40) | TLR7TLR8OPRM1OPRD1OPRK1 | |
| SCHEMBL21724877 | 0.85 | JAK1 (0.50) | OPRM1OPRD1OPRK1OGFRL1JAK1 | |
| SCHEMBL21724483 | 0.85 | NLRP3 (0.55) | TLR7TLR8JAK1 | |
| SCHEMBL23910159 | 0.79 | JAK1 (0.40) | OPRM1OPRD1OPRK1OGFRL1JAK1 | |
| SCHEMBL30777927 | 0.79 | JAK1 (0.40) | OPRM1OPRD1OPRK1OGFRL1JAK1 | |
| SCHEMBL22336632 | 0.75 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL31709368 | 0.75 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL31337596 | 0.75 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL23037686 | 0.74 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL30539819 | 0.74 | TLR7 (0.42) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3837015-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3837015-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112996567-A | Imidazo [4,5-C ] quinoline-derived NLRP 3-modulators | 先天肿瘤免疫公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR7 236/4885TLR8 210/4885OPRM1 3660/4885 |
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TLR7 236/4885TLR8 210/4885OPRM1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.